These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 15878318)
1. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318 [TBL] [Abstract][Full Text] [Related]
2. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. Greenspan SL; Beck TJ; Resnick NM; Bhattacharya R; Parker RA J Bone Miner Res; 2005 Sep; 20(9):1525-32. PubMed ID: 16059624 [TBL] [Abstract][Full Text] [Related]
3. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. Borggrefe J; Graeff C; Nickelsen TN; Marin F; Glüer CC J Bone Miner Res; 2010 Mar; 25(3):472-81. PubMed ID: 19778182 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744 [TBL] [Abstract][Full Text] [Related]
5. The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. Ito M; Oishi R; Fukunaga M; Sone T; Sugimoto T; Shiraki M; Nishizawa Y; Nakamura T Osteoporos Int; 2014 Mar; 25(3):1163-72. PubMed ID: 24345886 [TBL] [Abstract][Full Text] [Related]
6. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700 [TBL] [Abstract][Full Text] [Related]
7. The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk. Sone T; Ito M; Fukunaga M; Tomomitsu T; Sugimoto T; Shiraki M; Yoshimura T; Nakamura T Bone; 2014 Jul; 64():75-81. PubMed ID: 24727160 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504 [TBL] [Abstract][Full Text] [Related]
10. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis]. Takada J; Iba K; Yamashita T; Yoshizaki T Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365 [TBL] [Abstract][Full Text] [Related]
11. Geometric indices of bone strength are associated with physical activity and dietary calcium intake in healthy older women. Nurzenski MK; Briffa NK; Price RI; Khoo BC; Devine A; Beck TJ; Prince RL J Bone Miner Res; 2007 Mar; 22(3):416-24. PubMed ID: 17147487 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience. Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620 [TBL] [Abstract][Full Text] [Related]
13. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818 [TBL] [Abstract][Full Text] [Related]
14. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890 [TBL] [Abstract][Full Text] [Related]
15. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968 [TBL] [Abstract][Full Text] [Related]
16. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808 [TBL] [Abstract][Full Text] [Related]
17. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. Zanchetta JR; Bogado CE; Ferretti JL; Wang O; Wilson MG; Sato M; Gaich GA; Dalsky GP; Myers SL J Bone Miner Res; 2003 Mar; 18(3):539-43. PubMed ID: 12619939 [TBL] [Abstract][Full Text] [Related]
18. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645 [TBL] [Abstract][Full Text] [Related]
19. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. Duan Y; Beck TJ; Wang XF; Seeman E J Bone Miner Res; 2003 Oct; 18(10):1766-74. PubMed ID: 14584886 [TBL] [Abstract][Full Text] [Related]
20. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. Aspenberg P; Genant HK; Johansson T; Nino AJ; See K; Krohn K; García-Hernández PA; Recknor CP; Einhorn TA; Dalsky GP; Mitlak BH; Fierlinger A; Lakshmanan MC J Bone Miner Res; 2010 Feb; 25(2):404-14. PubMed ID: 19594305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]